Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC: a Metroticket Approach

NCT06294808 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT06294808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06294808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC: a Metroticket Approach
Lead sponsor
National Cancer Centre, Singapore
Phase
Observational
Overall status
Completed
Start date
July 17, 2017
Completion date
June 30, 2020
Enrollment
1,043 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma resectable